| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于调节ATP2A2表达的组合物和方法 | CN201380037612.1 | 2013-05-16 | CN104583401A | 2015-04-29 | 阿瑟·M·克里格; 罗梅什·苏布拉马尼安; 詹姆斯·麦克斯维根; 珍妮·T·李 |
| 本发明的方面提供用于激活或增强ATP2A2的表达的单链寡核苷酸。另外的方面提供包含用于激活或增强ATP2A2的表达的单链寡核苷酸的组合物和试剂盒。还提供了用于使用这些单链寡核苷酸调节ATP2A2的表达的方法。本发明的另外的方面提供了选择用于激活或增强ATP2A2的表达的候选寡核苷酸的方法。 | ||||||
| 2 | Compositions and methods for improving the functional efficacy of stem cell-derived cardiomyocytes | US12677790 | 2008-09-11 | US09045731B2 | 2015-06-02 | Ronald Li; Chung-wah Siu; Deborah K. Lieu; Jing Liu |
| This invention provides an isolated stem cell that has been modified to provide, enhance or contain the functional characteristics of the sarcoplasmic reticulum (SR). The isolated stem cells are modified in one or more of the following manners: by expressing a calcium channel protein; by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca2+-ATPase (SERCA) protein; by inhibiting or downregulating expression of the Na+/Ca+ exchanger (NCX) protein; by expressing a calcium handling protein; by expressing a transverse (t-tubule; and/or by expressing a transverse (t-tubule biogenic protein. After the cell has been modified, it may be expanded to a substantially homogenous population of these cells or alternatively, differentiated to a more mature cell type. Compositions containing these cells and population of cells are also provided by this invention. The cells and compositions can he used to regenerate cardiac tissue, improve cardiac function, restore action potential of cardiac tissue; and treat or prevent cardiac malfunction. These methods can be achieved by administering an effective amount of a cell or population of cells or tissue of this invention to a host in need thereof. The cells and population of cells can be used diagnostically to screen drug or other therapeutic candidates. | ||||||
| 3 | Compositions and Methods for Improving the Functional Efficacy of Stem Cell-Derived Cardiomyocytes | US12677790 | 2008-09-11 | US20120014924A1 | 2012-01-19 | Ronald Li; Chung-wah Siu; Deborah K. Lieu; Jing Liu |
| This invention provides an isolated stem cell modified to provide, enhance or contain the functional characteristics of the sarcoplasmic reticulum (SR) The isolated stem cells are modified by expressing a calcium channel protein, by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca2+-ATPase (SERCA) protein, by inhibiting or downregulating expression of the Na+/Ca2+ exchanger (NCX) protein, by expressing a calcium handling protein, by expressing a transverse (t)-tubule, and/or by expressing a transverse (t)-tubule biogenic protein The modified cells may be expanded to a substantially homogenous population of these cells or differentiated to a more mature cell type Compositions are also provided The cells and compositions can be administered to a host and used to regenerate cardiac tissue, improve cardiac function, restore action potential of cardiac tissue, and treat or prevent cardiac malfunction Use for diagnostic screening of therapeutic candidates is also provided | ||||||
| 4 | METHODS AND COMPOSITIONS FOR CONSISTENT INTRACORONARY ADMINISTRATION OF A BIOLOGIC | US15490202 | 2017-04-18 | US20170296790A1 | 2017-10-19 | Brian Jaski |
| Some embodiments provided herein relate to methods, systems and kits for providing consistent intracoronary administration of a biologic to subjects having diverse coronary anatomies. In some embodiments, the biologic is an adeno-associated virus serotype 1 (AAV1) vector encoding sarcoplasmic/endoplasmic reticulum ATPase 2a (SERCA2a) protein. | ||||||
| 5 | COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 EXPRESSION | US14401214 | 2013-05-16 | US20150159160A1 | 2015-06-11 | Arthur M. Krieg; Romesh Subramanian; James McSwiggen; Jeannie T. Lee |
| Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Methods for modulating expression of ATP2A2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of ATP2A2. | ||||||
| 6 | 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法 | JP2016568038 | 2015-05-15 | JP2017521362A | 2017-08-03 | デジール ゲイリー |
| 本発明は、腎臓病および腎臓障害並びに膵臓病および膵臓障害を検出、治療、および予防する組成物および方法を含む。 | ||||||
| 7 | A method for adjusting the myocardial contractility in invivo | JP2006500911 | 2004-01-12 | JP2006518996A | 2006-08-24 | ジョルダーノ、フランク; ディルマン、ウルフガング、エイチ．; メストリル、ルーベン |
| うっ血性心不全の動物の心筋中のカルシウム輸送をｉｎ ｖｉｖｏで調節するための方法を開示する。 本方法によれば、（うっ血性心不全の発症と同時に低減する）カルシウムＡＴＰアーゼ活性、及び心筋収縮性が、この酵素を作動的にコードしている遺伝子を心臓に送達することによって増大される。 それだけには限らないが、アデノ随伴ウイルスベクターの使用を含めて、送達系が提供される。 この遺伝子産物の発現及び心筋の性能に対するその効果をモニターする方法も提供される。 | ||||||
| 8 | ＡＴＰ２Ａ２発現を調節するための組成物及び方法 | JP2015512843 | 2013-05-16 | JP2015523853A | 2015-08-20 | アーサー エム． クリーグ，; ロメシュ スブラマニアン，; ジェイムズ マクスウィゲン，; ジェニー ティー． リー， |
| 本発明のいくつかの態様は、ATP2A2の発現を活性化又は増大するための一本鎖オリゴヌクレオチドを提供する。別の態様は、ATP2A2の発現を活性化又は増大するための一本鎖オリゴヌクレオチドを含む組成物及びキットを提供する。また、前記一本鎖オリゴヌクレオチドを用いて、ATP2A2の発現を調節する方法も提供される。本発明のさらに別の態様は、ATP2A2の発現を活性化又は増大するための候補オリゴヌクレオチドを選択する方法を提供する。 | ||||||
| 9 | 小胞体カルシウムＡＴＰアーゼ動態指示薬及びその利用 | JP2012552773 | 2012-01-13 | JPWO2012096384A1 | 2014-06-09 | 御子柴 克彦; 克彦 御子柴; 松浦 徹; 松浦 徹; 嘉名与 佐藤 |
| 本発明の融合タンパク質は、小胞体カルシウムATPアーゼと、FRETの蛍光供与体と、蛍光受容体とを備え、蛍光供与体と蛍光受容体とのうち一方は、当該ATPアーゼのN末端側に連結され、他方は、当該一方と当該ATPアーゼとの間、又は、当該ATPアーゼにおけるSERCA2aの1〜6番目のアミノ酸、369〜380番目のアミノ酸、もしくは572〜583番目のアミノ酸に対応するアミノ酸配列内、に挿入されている。 | ||||||
| 10 | COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 EXPRESSION | EP13790212 | 2013-05-16 | EP2850182A4 | 2016-01-20 | KRIEG ARTHUR M; SUBRAMANIAN ROMESH; MCSWIGGEN JAMES; LEE JEANNIE T |
| 11 | METHOD FOR IN VIVO REGULATION OF CARDIAC MUSCLE CONTRACTILITY | EP04701534.2 | 2004-01-12 | EP1590001B1 | 2008-12-10 | DILLMAN, Wolfgang, H.; GIORDANO, Frank; MESTRIL, Ruben |
| 12 | SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE | EP08756669 | 2008-06-03 | EP2164330A4 | 2011-12-28 | ZSEBO KRISZTINA M; SENYEI ANDREW |
| The present invention provides methods for treating urinary incontinence, urethral sphincter dysfunction and/or bladder dysfunction by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof. | ||||||
| 13 | SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE | EP08756669.1 | 2008-06-03 | EP2164330A1 | 2010-03-24 | ZSEBO, Krisztina, M.; SENYEI, Andrew |
| The present invention provides methods for treating urinary incontinence, urethral sphincter dysfunction and/or bladder dysfunction by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof. | ||||||
| 14 | Compositions and Methods for Treating and Preventing Pancreatitis, Renal Injury and Cancer | US15311689 | 2015-05-15 | US20170107499A1 | 2017-04-20 | Gary Desir |
| The present invention includes compositions and methods for detecting, treating and preventing renal and pancreatic diseases and disorders. | ||||||
| 15 | Compositions and Methods for Improving the Functional Efficacy of Stem Cell-Derived Cardiomyocytes | US14726874 | 2015-06-01 | US20160045555A1 | 2016-02-18 | Ronald Li; Chung-wah Siu; Deborah K. Lieu; Jing Liu |
| An isolated stem cell that has been modified to provide, enhance orcontain the functional characteristics of the sarcoplasmic reticulum (SR). The isolated stem cells are modified in one or more of the following manners: by expressing a calcium channel protein; by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca2+-ATPase (SERCA) protein; by inhibiting or downregulating expression of the Na+/Ca2+ exchanger (NCX) protein; by expressing a calcium handling protein; by expressing a transverse (t)-tubule; and/or by expressing a transverse (t)-tubule biogenic protein. After the cell has been modified, it may be expanded to a substantially homogenous population of these cells or alternatively, differentiated to a more mature cell type. Compositions containing these cells and population of cells are also provided by this invention. The cells and compositions can be used to regenerate cardiac tissue, improve cardiac function, restore action potential of cardiac tissue; and treat or prevent cardiac malfunction. These methods can be achieved by administering an effective amount of a cell or population of cells or tissue of this invention to a host in need thereof. The cells and population of cells can be used diagnostically to screen drug or other therapeutic candidates. | ||||||
| 16 | METHODS FOR IMPROVING CARDIAC CONTRACTILITY | US14109460 | 2013-12-17 | US20140243387A1 | 2014-08-28 | Mark Mercola; Agustin Rojas-Munoz; Christine Wahlquist; Alexandre Colas; Roger J. Hajjar; Dongtak Jeong |
| The present invention relates to regulation of cardiac contractile function. The present invention is based on the discovery that microRNAs contribute to the loss of cardiac contractility. Specifically, miR-25 binds to SERCA2a which results in a loss of function and interferes with Ca2+ handling. Accordingly, the present invention relates to methods of increasing cardiac contractile function by inhibiting miR-25. The invention further provides methods to identify agents that can modulate miR-25 activity, including high throughput screening methods, and provides a means to identify agents that are useful for treating patients having cardiac contractile function associated disorders. | ||||||
| 17 | ENDOPLASMIC RETICULUM CALCIUM ATPASE KINETICS INDICATOR AND USE THEREOF | US13979110 | 2012-01-13 | US20130323769A1 | 2013-12-05 | Katsuhiko Mikoshiba; Toru Matsu-Ura; Kanayo Satoh |
| The present invention provides a fusion protein including sarco/endoplasmic reticulum calcium ATPase, a fluorescence donor for FRET, and a fluorescence acceptor, one of the fluorescence donor and the fluorescence acceptor being linked to the N-terminus side of the ATPase, the other of the fluorescence donor and the fluorescence acceptor being inserted between the above one of the fluorescence donor and the fluorescence acceptor and the ATPase or being inserted in an amino acid sequence of the ATPase, the amino acid sequence corresponding to (i) amino acids 1 through 6 in SERCA2a, (ii) amino acids 369 through 380 in the SERCA2a or (iii) amino acids 572 through 583 in the SERCA2a. | ||||||
| 18 | ENGINEERED PROTEIN: "2-COLOR SERCA", AN ION-MOTIVE ATPase FUSED TO CERULEAN AND YELLOW FLUORESCENT PROTEIN | US13785837 | 2013-03-05 | US20130231262A1 | 2013-09-05 | Seth L. Robia |
| A method and engineered proteins for use therewith suitable for studying SERCA that are capable of being used in vivo and do not require protein purification or chemical labeling of SERCA, or reconstitution into artificial membranes. The engineered protein for calcium handling within human cells includes a two-color SERCA construct having three component proteins fused together. The three component proteins include a blue fluorescent protein (cerulean), SERCA2a and a yellow fluorescent protein (YFP), or a red fluorescent protein (tagRFP acceptor), SERCA and a green fluorescent protein (GFP). The method of determining SERCA activity for optimization of cardiac function includes resolving structure changes of the two-color SERCA construct. The two-color SERCA constructs are catalytically active and able to pump calcium following the step of resolving structure changes. | ||||||
| 19 | Methods for treating restenosis | US12951721 | 2010-11-22 | US08133878B1 | 2012-03-13 | Roger J. Hajjar; Anne-Marie Lompr; Larissa Lipskaia; Federica del Monte |
| Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel. | ||||||
| 20 | SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE | US12132533 | 2008-06-03 | US20080312177A1 | 2008-12-18 | Krisztina M. Zsebo; Andrew Senyei |
| The present invention provides methods for treating urinary incontinence, urethral sphincter dysfunction and/or bladder dysfunction by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof. | ||||||
QQ群二维码
意见反馈
意见反馈